期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 5, 页码 2547-2556出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b01547
关键词
-
资金
- Summit Therapeutics plc
- Medical Research Council [EP/L016044/1, 1501AV003/CA2]
- Engineering and Physical Sciences Research Council [EP/L016044/1]
- Duchenne UK
- MRC [MR/N010698/1] Funding Source: UKRI
5-(Ethylsulfonyl)-2-( naphthalen-2-yl) benzo[d]-oxazole (ezutromid, 1) is a first-in-class utrophin modulator that has been evaluated in a phase 2 clinical study for the treatment of Duchenne muscular dystrophy (DMD). Ezutromid was found to undergo hepatic oxidation of its 2-naphthyl substituent to produce two regioisomeric 1,2-dihydronaphthalene-1,2-diols, DHD1 and DHD3, as the major metabolites after oral administration in humans and rodents. In many patients, plasma levels of the DHD metabolites were found to exceed those of ezutromid. Herein, we describe the structural elucidation of the main metabolites of ezutromid, the regio- and relative stereochemical assignments of DHD1 and DHD3, their de novo chemical synthesis, and their production in systems in vitro. We further elucidate the likely metabolic pathway and CYP isoforms responsible for DHD1 and DHD3 production and characterize their physicochemical, ADME, and pharmacological properties and their preliminary toxicological profiles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据